

Arturo Pereira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8479275/publications.pdf>

Version: 2024-02-01

106
papers

4,137
citations

201674

27
h-index

114465

63
g-index

114
all docs

114
docs citations

114
times ranked

3650
citing authors

#	ARTICLE	IF	CITATIONS
1	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 37-43.	2.8	10
2	Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era. <i>Annals of Hematology</i> , 2022, 101, 59-67.	1.8	9
3	Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. <i>British Journal of Haematology</i> , 2022, 196, 649-659.	2.5	6
4	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	2.4	11
5	The Density of Renal Lymphatics Correlates With Clinical Outcomes in IgA Nephropathy. <i>Kidney International Reports</i> , 2022, 7, 823-830.	0.8	4
6	Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. <i>Transfusion</i> , 2022, 62, 974-981.	1.6	9
7	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.8	3
8	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. <i>Cancer</i> , 2022, 128, 2441-2448.	4.1	14
9	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	7.2	34
10	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	4.1	17
11	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 619.e1-619.e8.	1.2	15
12	Vasovagal syncope after blood donation in active duty military personnel of the Spanish Army. <i>Transfusion</i> , 2021, 61, 2925-2929.	1.6	1
13	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14
14	IgA Nephropathy Recurrence after Kidney Transplantation: Role of Recipient Age and Human Leukocyte Antigen-B Mismatch. <i>American Journal of Nephrology</i> , 2020, 51, 357-365.	3.1	8
15	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2020, 99, 791-798.	1.8	17
16	Hemorrhage Is a Major Cause of Blood Transfusion in COVID-19 Patients. <i>Blood</i> , 2020, 136, 21-22.	1.4	2
17	Intraoperative Transfusion of Red Blood Cell Units Stored >14 Days is Associated with an Increased Risk of Prosthetic Joint Infection. <i>Journal of Bone and Joint Infection</i> , 2019, 4, 85-91.	1.5	3
18	Positive direct antiglobulin test in post-artesunate delayed haemolysis: more than a coincidence?. <i>Malaria Journal</i> , 2019, 18, 123.	2.3	20

#	ARTICLE	IF	CITATIONS
19	Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry. <i>Blood</i> , 2019, 134, 1082-1082.	1.4	0
20	On the cost-utility of methylene blue-photoactivated plasma versus quarantine plasma in Spain. <i>Blood Transfusion</i> , 2019, 17, 83.	0.4	0
21	Red blood cell alloimmunisation: still a major complication of blood transfusion. <i>British Journal of Haematology</i> , 2018, 181, 575-576.	2.5	2
22	Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , 2018, 97, 813-820.	1.8	7
23	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. <i>Leukemia</i> , 2018, 32, 1427-1434.	7.2	48
24	Single Antigen- mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1196-1202.	2.0	50
25	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 181, 397-400.	2.5	34
26	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	6.2	38
27	The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. <i>Leukemia</i> , 2018, 32, 2082-2094.	7.2	1
28	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. <i>Blood</i> , 2018, 132, 47-47.	1.4	1
29	Excess Mortality in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2018, 132, 3042-3042.	1.4	2
30	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. <i>Blood</i> , 2018, 132, 3103-3103.	1.4	0
31	Kinetics of Iron Depletion in Hereditary Hemochromatosis. <i>Blood</i> , 2018, 132, 3630-3630.	1.4	1
32	Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4576-4576.	1.4	0
33	Massive erythrophagocytosis by peripheral monocytes and neutrophils in parvovirus-B19 autoimmune hemolytic anemia. <i>Annals of Hematology</i> , 2017, 96, 881-882.	1.8	11
34	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017, 178, 764-771.	2.5	22
35	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. <i>American Journal of Hematology</i> , 2017, 92, E534-E541.	4.1	6
36	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2017, 99, 36-41.	2.2	3

#	ARTICLE	IF	CITATIONS
37	Closer than expected: central vein catheters and perplexing laboratory results. <i>Transfusion</i> , 2017, 57, 499-500.	1.6	0
38	Does ruxolitinib prolong the survival of patients with myelofibrosis?. <i>Blood</i> , 2017, 129, 832-837.	1.4	81
39	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. <i>Leukemia Research</i> , 2017, 63, 85-89.	0.8	9
40	Excess mortality in the myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017, 92, 149-154.	4.1	15
41	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , 2017, 96, 81-85.	1.8	28
42	Transfusion of Packed Red Blood Cells Stored >14 Days was Associated with a Higher Risk of Infection after HIP Revision Arthroplasty. <i>HIP International</i> , 2016, 26, 132-137.	1.7	4
43	Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 96, 285-290.	2.2	17
44	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	3.5	118
45	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 322-327.	2.8	7
46	Regarding: Advances in hepatectomy technique: Toward zero transfusions in the modern era of liver surgery. <i>Surgery</i> , 2016, 160, 247-248.	1.9	0
47	Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4331-4331.	1.4	0
48	Transfusion and inpatient 30-day mortality. <i>Transfusion</i> , 2015, 55, 461-462.	1.6	0
49	Propofol as a cause of lipemic plasma. <i>Transfusion</i> , 2015, 55, 946-946.	1.6	3
50	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , 2015, 125, 3347-3350.	1.4	152
51	Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. <i>Leukemia Research</i> , 2015, 39, 1146-1153.	0.8	15
52	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , 2015, 94, 1791-1796.	1.8	57
53	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 609-609.	1.4	5
54	Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD). <i>Blood</i> , 2015, 126, 1672-1672.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 5464-5464.	1.4	0
56	Survival analysis in hematologic malignancies: recommendations for clinicians. <i>Haematologica</i> , 2014, 99, 1410-1420.	3.5	103
57	Who advocates for cryoprecipitate?. <i>Transfusion</i> , 2014, 54, 1442-1443.	1.6	4
58	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 874-881.	0.8	16
59	Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 73-79.	0.4	4
60	Length of Storage of Transfused Red Blood Cells and Risk of Prosthetic Joint Infection After Primary Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2014, 29, 2016-2020.	3.1	17
61	Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. <i>Haematologica</i> , 2014, 99, 1599-1604.	3.5	56
62	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. <i>Blood</i> , 2014, 124, 633-633.	1.4	0
63	Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model. <i>Blood</i> , 2014, 124, 4660-4660.	1.4	0
64	Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome. <i>Blood</i> , 2014, 124, 4636-4636.	1.4	0
65	Will clinical studies elucidate the connection between the length of storage of transfused red blood cells and clinical outcomes? An analysis based on the simulation of randomized controlled trials. <i>Transfusion</i> , 2013, 53, 34-40.	1.6	47
66	Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. <i>Transfusion</i> , 2013, 53, 710-715.	1.6	77
67	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 104-104.	1.4	3
68	Evaluation Of Two Prognostic Scoring Systems For Chronic Myelomonocytic Leukemia (CMML): CMML-Specific Prognostic Scoring System (CPSS) and MD Anderson Prognostic Score (MDAPS) In A Series Of 122 Cases Of De Novo CMML. <i>Blood</i> , 2013, 122, 2810-2810.	1.4	2
69	Clinical Monoclonal B Lymphocytosis (cMBL), Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Diagnostic Criteria, Features At Diagnosis and Natural History. <i>Blood</i> , 2013, 122, 5273-5273.	1.4	0
70	Prognostication in Primary Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 43-49.	2.3	19
71	Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. <i>American Journal of Hematology</i> , 2011, 86, 245-250.	4.1	30
72	Reversion of the Experimental Hemodilutional Coagulopathy Induced by Crystalloids and Colloids Using Different Coagulation Factor Concentrates. <i>Blood</i> , 2011, 118, 4349-4349.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. <i>Blood</i> , 2010, 115, 745-746.	1.4	0
74	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). <i>Blood</i> , 2010, 115, 1703-1708.	1.4	805
75	Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. <i>Annals of Hematology</i> , 2009, 88, 973-978.	1.8	15
76	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2009, 113, 2895-2901.	1.4	1,110
77	BAFF and APRIL in Chronic Lymphocytic Leukemia: Clinico-Biological Correlates and Prognostic Significance.. <i>Blood</i> , 2009, 114, 1235-1235.	1.4	1
78	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. <i>Blood</i> , 2009, 114, 3891-3891.	1.4	0
79	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. <i>Blood</i> , 2009, 114, 1113-1113.	1.4	0
80	The Prognostic Significance of Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2361-2361.	1.4	0
81	Methylene blueâ€photoinactivated plasma <i>versus</i> quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. <i>British Journal of Haematology</i> , 2008, 143, 39-45.	2.5	57
82	A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2008, 112, 657-657.	1.4	4
83	Newly-Diagnosed Versus Non-Initial Episodes of Thrombotic Thrombocytopenic Purpura: A Comparison of Presenting Clinical Characteristics and Response to Treatment.. <i>Blood</i> , 2008, 112, 2287-2287.	1.4	2
84	Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. <i>Haematologica</i> , 2007, 92, 846-849.	3.5	41
85	Alterations of ADAMTS-13 Activity as a Common Indicator of the Endothelial Dysfunction Developing in Different Thrombotic Microangiopathies.. <i>Blood</i> , 2006, 108, 4091-4091.	1.4	0
86	Performance of time-series methods in forecasting the demand for red blood cell transfusion. <i>Transfusion</i> , 2004, 44, 739-746.	1.6	32
87	Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. <i>Transfusion</i> , 2003, 43, 192-201.	1.6	32
88	DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of Pâ€selectin sialylated ligands on the monocyte surface. <i>British Journal of Haematology</i> , 2003, 120, 814-820.	2.5	11
89	Determinants of costs in blood services: blood transfusion from an economic perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2002, 2, 201-210.	1.4	5
90	Do patient-related blood donors represent a threat to the safety of the blood supply?. <i>Haematologica</i> , 2002, 87, 427-33.	3.5	11

#	ARTICLE	IF	CITATIONS
91	Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion, 2001, 41, 762-765.	1.6	50
92	Health and economic consequences of HCV lookback. Transfusion, 2001, 41, 832-839.	1.6	12
93	Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion, 2001, 41, 1548-1552.	1.6	67
94	Cost-effectiveness analysis and the selection of blood products. Current Opinion in Hematology, 2000, 7, 420-425.	2.5	11
95	The above letter was sent to Dr. Pereira, who submitted the following reply.. Transfusion, 2000, 40, 125-127.	1.6	1
96	A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion, 2000, 40, 1182-1191.	1.6	36
97	Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 1998, 102, 684-690.	2.5	168
98	The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. European Journal of Haematology, 1998, 60, 101-105.	2.2	36
99	Anti-“Sia-Ib (Anti-Gd) Cold Agglutinins Bind the Domain NeuNAc1±2-3Gal in Sialyl Lewisx, Sialyl Lewis, and Related Carbohydrates on Nucleated Cells and in Soluble Cancer-Associated Mucins. Blood, 1997, 90, 1576-1587.	1.4	14
100	Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. British Journal of Haematology, 1997, 97, 635-640.	2.5	164
101	Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. British Journal of Haematology, 1996, 93, 220-224.	2.5	50
102	Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. British Journal of Haematology, 1994, 87, 293-300.	2.5	25
103	Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation. European Journal of Haematology, 1990, 44, 95-99.	2.2	25
104	Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. British Journal of Haematology, 1988, 70, 279-282.	2.5	25
105	Early T-cell features in blast crisis of Ph ⁺ “positive chronic myeloid leukaemia. Scandinavian Journal of Haematology, 1985, 35, 71-76.	0.0	8
106	Accurately assessing risk in your myeloproliferative neoplasm patient. , 0, , 37-44.		0